Gene therapy's debated cancer risk: new cases strengthen the evidence

For many years, researchers in the gene therapy field have debated whether the adeno-associated viruses (AAVs) used to deliver replacement genes into cells could, in a small number of cases, trigger tumour formation through insertional mutagenesis — the disruption of a tumour-suppressor gene or activation of an oncogene at the viral integration site. According to reporting by STAT News on 9–10 November 2026, a small number of cases have now emerged that provide what observers describe as strong evidence that this risk, while rare, is real.

The story connects to previously reported tumour cases in children treated with Novartis's Zolgensma (onasemnogene abeparvovec), the AAV9-based gene therapy for spinal muscular atrophy, which Genetic Current covered on 6 and 8 November 2026. The STAT reporting frames the broader question for the field: not whether a specific product is uniquely implicated, but whether insertional mutagenesis from AAV vectors is a class-level concern that the gene therapy community must now treat as an established, if infrequent, phenomenon rather than a theoretical risk.

The cases appear to be a small fraction of the thousands of patients treated globally, and no causal mechanism has been confirmed in every instance. Researchers and regulators are now working to understand which vector designs, doses, target tissues, and patient populations carry the greatest exposure. The findings are likely to influence pharmacovigilance requirements, long-term follow-up protocols, and informed-consent practices for future AAV gene therapy trials and approved products. No regulatory action beyond existing pharmacovigilance was announced in the reporting reviewed.